Trial Profile
A European Open-Label, Multicentre, Phase II Study of Inolimomab in the Treatment of Primary Steroid Resistant Acute Graft versus Host Disease (aGvHD) following allogeneic Stem Cell Transplantation for Hematological Malignancies in Adult patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2012
Price :
$35
*
At a glance
- Drugs Inolimomab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors OPi
- 26 Jun 2012 New trial record